Even as he observes that the in vitro diagnostics (IVD) industry is slow-growing at the moment and has only limited resources to spend on development of next-generation products, Emery Stephans lauds the industry's future. Despite others' skepticism, he's excited by the promise of pharmacogenomics (although the timing of a take-off is unknown), analyte specific reagents (ASRs, which he calls a "brilliant" regulatory concept), and consumerism as driving forces in diagnostics. "There is reason to be highly optimistic about the future, for both in vitro and more rapidly evolving in vivo imaging," he insists.
A small, energetic man who heads Enterprise Analysis Corp. in Stamford, CT, Stephans has been consulting to IVD and medical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?